Using Plasmids as DNA Vaccines for Infectious Diseases

Tregoning, John S.; Kinnear, Ekaterina

doi:10.1128/microbiolspec.plas-0028-2014

Cited by 61 publications

(45 citation statements)

References 163 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…DNA vaccines allow the induction of strong cellular responses (16), and the use of different targeting modules allows us to compare the relative contributions of different effectors (17). We compared the response to immunization using a DNA vaccine encoding dimeric APC-targeted antigen alone or in combination with protein antigens.…”

Section: Resultsmentioning

confidence: 99%

DNA Vaccines Encoding Antigen Targeted to MHC Class II Induce Influenza-Specific CD8+ T Cell Responses, Enabling Faster Resolution of Influenza Disease

et al. 2016

Self Cite

View full text Add to dashboard Cite

Current influenza vaccines are effective but imperfect, failing to cover against emerging strains of virus and requiring seasonal administration to protect against new strains. A key step to improving influenza vaccines is to improve our understanding of vaccine induced protection. Whilst it is clear that antibodies play a protective role, vaccine induced CD8+ T cells can improve protection. To further explore the role of CD8+ T cells we used a DNA vaccine that encodes antigen dimerised to an immune cell targeting module. Immunising CB6F1 mice with the DNA vaccine in a heterologous prime boost regime with the seasonal protein vaccine improved the resolution of influenza disease compared to protein alone. This improved disease resolution was dependent on CD8+ T cells. However, DNA vaccine regimes that induced CD8+ T cells alone were not protective and did not boost the protection provided by protein. The MHC targeting module used was an anti-I-Ed single chain antibody specific to the BALB/c strain of mice. To test the role of MHC targeting we compared the response between BALB/c, C57BL/6 mice and an F1 cross of the two strains (CB6F1). BALB/c mice were protected, C57BL/6 were not and the F1 had an intermediate phenotype; showing that the targeting of antigen is important in the response. Based on these findings, and in agreement with other studies using different vaccines, we conclude that in addition to antibody, inducing a protective CD8 response is important in future influenza vaccines

show abstract

Section: Resultsmentioning

confidence: 99%

DNA Vaccines Encoding Antigen Targeted to MHC Class II Induce Influenza-Specific CD8+ T Cell Responses, Enabling Faster Resolution of Influenza Disease

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…Inflammation is rarely seen in response to DNA vaccine administration in humans, particularly if the vaccine is administered using a needle and syringe and no non-DNA boost, such as recombinant protein antigen or an adenoviral vector-based vaccine, is given 20 . It is possible that the inflammation is in part due to the mode of delivery as a recent clinical trial comparing vaccine given IM and ID indicated that while ID resulted in more inflammation at the injection site than IM, the measured immunogenicity resulting from the 2 sites was similar 22 .…”

Section: Discussionmentioning

confidence: 99%

An escalating dose study to assess the safety, tolerability and immunogenicity of a Herpes Simplex Virus DNA vaccine, COR-1

Dutton

Woo

Chandra

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

This paper describes a single site, open-label Phase I clinical trial evaluating the safety, tolerability and immunogenicity in healthy volunteers of a herpes simplex polynucleotide vaccine that has previously been shown to enhance immunogenicity and protect against lethal herpes simplex virus type 2 (HSV-2) challenge in mice. Five escalating doses of the vaccine, COR-1, were given by intradermal injection to HSV-1 and 2 seronegative healthy individuals. COR-1 was found to be safe and well-tolerated; the only vaccine-related adverse events were mild. While vaccine-induced antibody responses were not detectable, cell-mediated immune responses to HSV-specific peptide groups were identified in 19 of the 20 subjects who completed the study, and local inflammation at the immunisation site was observed. This study indicates COR-1 has potential to be used as a therapeutic vaccine for HSV-2 infection.

show abstract

“…Since there is no efficient tissue culture system for cultivation of HEV, the recombinant DNA technology is the only approach in developing an HEV vaccine (27). To achieve this, DNA vaccines have been discovered to have several advantages including cost-effective, stability, and higher immunogenicity of a target antigen (28). Numerous reports revealed that the effectiveness of immune responses have been stimulated by DNA vaccines (29).…”

Section: Discussionmentioning

confidence: 99%

Cloning and Expression of a Secretory form of Truncated ORF2 (aa 112-607) from Hepatitis E Virus in the pVAX1 Vector

Makvandi

Taherkhani

Azizolahi

2017

Jundishapur J Microbiol

View full text Add to dashboard Cite

Background: The hepatitis E virus (HEV) accounts for the hepatitis E infection with a high mortality rate in pregnant women. Therefore, the design of the novel and effective vaccines seems essential and the DNA vaccine approach could be useful to achieve this anticipated goal. Objectives: The aim of this study was the cloning of a secretory form of truncated open reading frame 2 (ORF2) of HEV containing amino acids (aa) 112 -607 into the eukaryotic expression pVAX1 Vector and evaluating of the expression of this recombinant protein in eukaryotic cells. Methods: The truncated ORF2 gene (aa 112 -607) was cloned in the pVAX1 plasmid by restriction enzyme digest and confirmed by digestion and sequencing. Then, the recombinant plasmid was transfected into eukaryotic cells to express the recombinant protein.The expressed protein in the cell lysate and supernatant was evaluated by immunofluorescence assay (IFA) and western blot assay. Results: Colony polymerase chain reactions (PCR), restriction enzyme digestion, along with DNA sequencing of the recombinant plasmid were performed for confirmation of cloning tPA-PADRE-truncated ORF2 gene (aa 112 -607) into pVAX1 eukaryotic expression vector. The appearance of the truncated ORF2 protein (56 kDa) in the eukaryotic cells was accepted by the western blot assay, reverse transcription polymerase chain reaction (RT-PCR) method, as well as IFA. Conclusions: All outcomes of the present research showed that pVAX1-tPA-PADRE-truncated ORF2 (aa 112 -607, 56 kDa) recombinant plasmid was able to express truncated ORF2 from HEV as a potential candidate vaccine.

show abstract

Using Plasmids as DNA Vaccines for Infectious Diseases

Cited by 61 publications

References 163 publications

DNA Vaccines Encoding Antigen Targeted to MHC Class II Induce Influenza-Specific CD8+ T Cell Responses, Enabling Faster Resolution of Influenza Disease

DNA Vaccines Encoding Antigen Targeted to MHC Class II Induce Influenza-Specific CD8+ T Cell Responses, Enabling Faster Resolution of Influenza Disease

An escalating dose study to assess the safety, tolerability and immunogenicity of a Herpes Simplex Virus DNA vaccine, COR-1

Cloning and Expression of a Secretory form of Truncated ORF2 (aa 112-607) from Hepatitis E Virus in the pVAX1 Vector

Contact Info

Product

Resources

About